Latest News

Solstice Oncology plans to begin enrolment in a Phase II clinical trial of porustobart in combination with pembrolizumab in the fourth quarter of 2026.

Encoded plans to use the proceeds primarily to fund a pivotal trial of ETX101 in infants and young children with SCN1A positive Dravet syndrome.

The rollout follows the drug’s approval in China in June 2026 and marks the start of its wider clinical use for people requiring urgent post-exposure protection against rabies.

The acquisition brings MLM’s laboratory infrastructure and scientific expertise into Labcorp’s global network, creating a broader platform to support clinical trials across multiple regions.

The partnership between KUTRRH and MTRH is expected to continue supporting the development of specialised renal services in Kenya.

The achievement also makes JHAH the only hospital system outside the United States to secure the distinction through a single, unified appraisal covering multiple hospitals and sites.

The three-day program will cover a wide range of pediatric neurological and neurosurgical conditions, from common disorders to complex and rare diseases.

Kerry will work with governments, development partners, multilateral institutions, civil society and the private sector to advocate for stronger health systems and more sustainable health financing.

Nyxoah plans to enrol and implant up to 229 patients at as many as 25 sites, with participants receiving follow-up for up to five years after implantation.

Although Aedes aegypti mosquitoes have been detected in the UK several times in recent years, the latest findings provide the first evidence that the species is actively breeding in Britain.